SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001193125-23-302201
Filing Date
2023-12-22
Accepted
2023-12-22 17:00:44
Documents
8
Effectiveness Date
2023-12-22

Document Format Files

Seq Description Document Type Size
1 S-8 d593177ds8.htm S-8 61886
2 EX-5.1 d593177dex51.htm EX-5.1 9960
3 EX-23.1 d593177dex231.htm EX-23.1 1907
4 EX-23.2 d593177dex232.htm EX-23.2 1807
5 EX-99.1 d593177dex991.htm EX-99.1 118651
6 EX-99.2 d593177dex992.htm EX-99.2 103384
7 EX-FILING FEES d593177dexfilingfees.htm EX-FILING FEES 28500
8 GRAPHIC g593177g1220180703557.jpg GRAPHIC 2179
  Complete submission text file 0001193125-23-302201.txt   330449
Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940
Spyre Therapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-276256 | Film No.: 231510637
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)